Jennifer L Shaw1, Renee Robinson, Helene Starks, Wylie Burke, Denise A Dillard. 1. Jennifer L. Shaw, Renee Robinson, and Denise A. Dillard are with the Southcentral Foundation Research Department, Anchorage, AK. Helene Starks and Wylie Burke are with the University of Washington, Seattle.
Abstract
OBJECTIVES: Pharmacogenetic research and clinical testing raise important concerns for individuals and communities, especially where past medical research and practice has perpetrated harm and cultivated distrust of health care systems and clinicians. We investigated perceptions of pharmacogenetics among Alaska Native (AN) people. METHODS: We held four focus groups for 32 ANs in south central Alaska to elicit views about pharmacogenetics in general and for treatment of cardiovascular disease, breast cancer, depression, and nicotine addiction. We analyzed data for perceived risks and rewards of pharmacogenetics. RESULTS: Potential risks of pharmacogenetics included health care rationing, misuse of information, and stigma to individuals and the AN community. Potential rewards included decreased care costs, improved outcomes, and community development. Participants also discussed 8 contingent conditions that could mitigate risks and increase pharmacogenetic acceptability. CONCLUSIONS: Alaska Natives perceive pharmacogenetics as potentially benefitting and harming individuals, communities, and health systems, depending on methods and oversight. Researchers, clinicians, and administrators, especially in community-based clinic and health care systems serving minority populations, must address this "double-edged sword" to effectively conduct pharmacogenetics.
OBJECTIVES: Pharmacogenetic research and clinical testing raise important concerns for individuals and communities, especially where past medical research and practice has perpetrated harm and cultivated distrust of health care systems and clinicians. We investigated perceptions of pharmacogenetics among Alaska Native (AN) people. METHODS: We held four focus groups for 32 ANs in south central Alaska to elicit views about pharmacogenetics in general and for treatment of cardiovascular disease, breast cancer, depression, and nicotine addiction. We analyzed data for perceived risks and rewards of pharmacogenetics. RESULTS: Potential risks of pharmacogenetics included health care rationing, misuse of information, and stigma to individuals and the AN community. Potential rewards included decreased care costs, improved outcomes, and community development. Participants also discussed 8 contingent conditions that could mitigate risks and increase pharmacogenetic acceptability. CONCLUSIONS: Alaska Natives perceive pharmacogenetics as potentially benefitting and harming individuals, communities, and health systems, depending on methods and oversight. Researchers, clinicians, and administrators, especially in community-based clinic and health care systems serving minority populations, must address this "double-edged sword" to effectively conduct pharmacogenetics.
Authors: Steven H Y Wong; Christopher Happy; Dan Blinka; Susan Gock; Jeffrey M Jentzen; Joseph Donald Hon; Howard Coleman; Saeed A Jortani; Yolande Lucire; Cynthia L Morris-Kukoski; Manuela G Neuman; Paul J Orsulak; Tara Sander; Michael A Wagner; Jennifer R Wynn; Alan H B Wu; Kiang-Teck J Yeo Journal: Pharmacogenomics Date: 2010-06 Impact factor: 2.533
Authors: Diana S Catz; Nancy S Green; Jonathan N Tobin; Michele A Lloyd-Puryear; Penny Kyler; Ann Umemoto; Jennifer Cernoch; Roxane Brown; Fredericka Wolman Journal: Community Genet Date: 2005
Authors: Amanda M Fretts; Barbara V Howard; Andrea M Kriska; Nicolas L Smith; Thomas Lumley; Elisa T Lee; Marie Russell; David Siscovick Journal: Am J Epidemiol Date: 2009-07-21 Impact factor: 4.897
Authors: Laura M Beskow; Jeffrey R Botkin; Mary Daly; Eric T Juengst; Lisa Soleymani Lehmann; Jon F Merz; Rebecca Pentz; Nancy A Press; Lainie Friedman Ross; Jeremy Sugarman; Lisa R Susswein; Sharon F Terry; Melissa A Austin; Wylie Burke Journal: Am J Med Genet A Date: 2004-11-01 Impact factor: 2.802
Authors: Vence L Bonham; Toby Citrin; Stephen M Modell; Tené Hamilton Franklin; Esther W B Bleicher; Leonard M Fleck Journal: J Health Polit Policy Law Date: 2009-06 Impact factor: 2.265
Authors: Alison E Fohner; Renee Robinson; Joseph Yracheta; Denise A Dillard; Brian Schilling; Burhan Khan; Scarlett Hopkins; Bert Boyer; Jynene Black; Howard Wiener; Hemant K Tiwari; Adam Gordon; Deborah Nickerson; Jesse M Tsai; Federico M Farin; Timothy A Thornton; Allan E Rettie; Kenneth E Thummel Journal: Pharmacogenet Genomics Date: 2015-07 Impact factor: 2.089
Authors: Jaedon P Avey; Vanessa Y Hiratsuka; Julie A Beans; Susan Brown Trinidad; Rachel F Tyndale; Renee F Robinson Journal: Pharmacogenomics Date: 2016-02-12 Impact factor: 2.533
Authors: Vanessa Y Hiratsuka; Julie A Beans; Lisa G Dirks; Jaedon P Avey; Karen Caindec; Denise A Dillard Journal: Am Indian Alsk Native Ment Health Res Date: 2018
Authors: Jaedon P Avey; Vanessa Y Hiratsuka; Lisa G Dirks; Laurie A Moore; Barbara Beach; Douglas K Novins; Karen Caindec; Denise A Dillard Journal: Am Indian Alsk Native Ment Health Res Date: 2018
Authors: Lisa G Dirks; Jennifer L Shaw; Vanessa Y Hiratsuka; Julie A Beans; Janet J Kelly; Denise A Dillard Journal: J Community Genet Date: 2019-01-30
Authors: Chelsea T Morales; LeeAnna I Muzquiz; Kevin Howlett; Bernie Azure; Brenda Bodnar; Vernon Finley; Tony Incashola; Cheryl Mathias; Cindi Laukes; Patrick Beatty; Wylie Burke; Mark A Pershouse; Elizabeth A Putnam; Susan Brown Trinidad; Rosalina James; Erica L Woodahl Journal: Prog Community Health Partnersh Date: 2016